235 related articles for article (PubMed ID: 20826787)
41. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Thangasamy T; Sittadjody S; Mitchell GC; Mendoza EE; Radhakrishnan VM; Limesand KH; Burd R
BMC Cancer; 2010 Jun; 10():282. PubMed ID: 20540768
[TBL] [Abstract][Full Text] [Related]
42. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
[TBL] [Abstract][Full Text] [Related]
43. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.
Brew CT; Aronchik I; Hsu JC; Sheen JH; Dickson RB; Bjeldanes LF; Firestone GL
Int J Cancer; 2006 Feb; 118(4):857-68. PubMed ID: 16152627
[TBL] [Abstract][Full Text] [Related]
44. p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG.
Thakur VS; Ruhul Amin AR; Paul RK; Gupta K; Hastak K; Agarwal MK; Jackson MW; Wald DN; Mukhtar H; Agarwal ML
Cancer Lett; 2010 Oct; 296(2):225-32. PubMed ID: 20444544
[TBL] [Abstract][Full Text] [Related]
45. Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity.
Majumdar D; Jung KH; Zhang H; Nannapaneni S; Wang X; Amin AR; Chen Z; Chen ZG; Shin DM
Cancer Prev Res (Phila); 2014 Jan; 7(1):65-73. PubMed ID: 24403290
[TBL] [Abstract][Full Text] [Related]
46. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
[TBL] [Abstract][Full Text] [Related]
47. Kaempferol induces apoptosis in human HCT116 colon cancer cells via the Ataxia-Telangiectasia Mutated-p53 pathway with the involvement of p53 Upregulated Modulator of Apoptosis.
Li W; Du B; Wang T; Wang S; Zhang J
Chem Biol Interact; 2009 Jan; 177(2):121-7. PubMed ID: 19028473
[TBL] [Abstract][Full Text] [Related]
48. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells.
Bhatia N; Agarwal C; Agarwal R
Nutr Cancer; 2001; 39(2):292-9. PubMed ID: 11759294
[TBL] [Abstract][Full Text] [Related]
49. EGCG induces apoptosis in human laryngeal epidermoid carcinoma Hep2 cells via mitochondria with the release of apoptosis-inducing factor and endonuclease G.
Lee JH; Jeong YJ; Lee SW; Kim D; Oh SJ; Lim HS; Oh HK; Kim SH; Kim WJ; Jung JY
Cancer Lett; 2010 Apr; 290(1):68-75. PubMed ID: 19781850
[TBL] [Abstract][Full Text] [Related]
50. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
[TBL] [Abstract][Full Text] [Related]
51. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.
Lin HY; Hou SC; Chen SC; Kao MC; Yu CC; Funayama S; Ho CT; Way TD
J Agric Food Chem; 2012 Mar; 60(10):2480-9. PubMed ID: 22313388
[TBL] [Abstract][Full Text] [Related]
52. Epigallocatechin gallate induced apoptosis in Sarcoma180 cells in vivo: mediated by p53 pathway and inhibition in U1B, U4-U6 UsnRNAs expression.
Manna S; Banerjee S; Mukherjee S; Das S; Panda CK
Apoptosis; 2006 Dec; 11(12):2267-76. PubMed ID: 17041754
[TBL] [Abstract][Full Text] [Related]
53. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin.
Chiang CT; Way TD; Lin JK
Mol Cancer Ther; 2007 Jul; 6(7):2127-38. PubMed ID: 17620442
[TBL] [Abstract][Full Text] [Related]
54. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro.
Li GX; Chen YK; Hou Z; Xiao H; Jin H; Lu G; Lee MJ; Liu B; Guan F; Yang Z; Yu A; Yang CS
Carcinogenesis; 2010 May; 31(5):902-10. PubMed ID: 20159951
[TBL] [Abstract][Full Text] [Related]
55. Anti-cancer effect of (-)-epigallocatechin-3-gallate (EGCG) in head and neck cancer through repression of transactivation and enhanced degradation of β-catenin.
Shin YS; Kang SU; Park JK; Kim YE; Kim YS; Baek SJ; Lee SH; Kim CH
Phytomedicine; 2016 Nov; 23(12):1344-1355. PubMed ID: 27765354
[TBL] [Abstract][Full Text] [Related]
56. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
57. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
58. Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway.
Iida K; Naiki T; Naiki-Ito A; Suzuki S; Kato H; Nozaki S; Nagai T; Etani T; Nagayasu Y; Ando R; Kawai N; Yasui T; Takahashi S
Cancer Sci; 2020 Apr; 111(4):1165-1179. PubMed ID: 31994822
[TBL] [Abstract][Full Text] [Related]
59. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells.
Sahu RP; Batra S; Srivastava SK
Br J Cancer; 2009 May; 100(9):1425-33. PubMed ID: 19401701
[TBL] [Abstract][Full Text] [Related]
60. D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Juang SH; Lung CC; Hsu PC; Hsu KS; Li YC; Hong PC; Shiah HS; Kuo CC; Huang CW; Wang YC; Huang L; Chen TS; Chen SF; Fu KC; Hsu CL; Lin MJ; Chang CJ; Ashendel CL; Chan TC; Chou KM; Chang JY
Mol Cancer Ther; 2007 Jan; 6(1):193-202. PubMed ID: 17237279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
